Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma

References

• CriscioneVDWeinstockMAIncidence of cutaneous T-cell lymphoma in the United States, 1973–2002Arch Dermatol200714385485917638728
   PubMed Web of Science ®Google Scholar
• LansiganFChoiJFossFMCutaneous T-cell lymphomaHematol Oncol Clin North Am200822979996 x.18954747
   PubMed Web of Science ®Google Scholar
• BunnPAJLambergSIReport of the Committee on Staging and Classification of Cutaneous T-Cell LymphomasCancer Treat Rep197963725728445521
   PubMedGoogle Scholar
• SausvilleEAEddyJLMakuchRWHistopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groupsAnn Intern Med19881093723823408055
   PubMed Web of Science ®Google Scholar
• DemierreMFKimYHZackheimHSPrognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphomaHematol Oncol Clin North Am2003171485150714710899
   PubMed Web of Science ®Google Scholar
• VonderheidECBernengoMGBurgGUpdate on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous LymphomasJ Am Acad Dermatol2002469510611756953
   PubMed Web of Science ®Google Scholar
• KimYHLiuHLMraz-GernhardSVargheseAHoppeRTLong-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progressionArch Dermatol200313985786612873880
   PubMed Web of Science ®Google Scholar
• HealdPProbing the immune dysregulation in cutaneous T-cell lymphomasJ Invest Dermatol2005125xvixvii16354175
   PubMed Web of Science ®Google Scholar
• BachaPWilliamsDPWatersCWilliamsJMMurphyJRStromTBInterleukin 2 receptor-targeted cytotoxicity. Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion proteinJ Exp Med19881676126223126255
   PubMed Web of Science ®Google Scholar
• FossFMDAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technologyClin Lymphoma20001Suppl 1S273111707860
   PubMedGoogle Scholar
• HatakeyamaMMinamotoSUchiyamaTHardyRRYamadaGTaniguchiTReconstitution of functional receptor for human interleukin-2 in mouse cellsNature19853184674703934560
   PubMed Web of Science ®Google Scholar
• LeonardWJDepperJMCrabtreeGRMolecular cloning and expression of cDNAs for the human interleukin-2 receptorNature19843116266316090948
   PubMed Web of Science ®Google Scholar
• TakeshitaTAsaoHOhtaniKCloning of the gamma chain of the human IL-2 receptorScience19922573793821631559
   PubMed Web of Science ®Google Scholar
• TsudoMKitamuraFMiyasakaMCharacterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodiesProc Natl Acad Sci U S A198986198219862467293
   PubMed Web of Science ®Google Scholar
• MorrisJCWaldmannTAAdvances in interleukin 2 receptor targeted treatmentAnn Rheum Dis200059Suppl 1i109i11411053100
   PubMed Web of Science ®Google Scholar
• FossFClinical experience with denileukin diftitox (ONTAK)Semin Oncol200633S11S1616516670
   PubMed Web of Science ®Google Scholar
• SakaguchiSSakaguchiNAsanoMItohMTodaMImmunologic self-tolerance maintained by activated T-cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseasesJ Immunol1995155115111647636184
   PubMed Web of Science ®Google Scholar
• RandolphDAFathmanCGCd4+ Cd25+ regulatory T-cells and their therapeutic potentialAnnu Rev Med20065738140216409156
   PubMed Web of Science ®Google Scholar
• BergerCLTigelaarRCohenJCutaneous T-cell lymphoma: malignant proliferation of T-regulatory cellsBlood20051051640164715514008
   PubMed Web of Science ®Google Scholar
• DepperJMLeonardWJKronkeMWaldmannTAGreeneWCAugmented T-cell growth factor receptor expression in HTLV-1-infected human leukemic T-cellsJ Immunol1984133169116956088625
   PubMed Web of Science ®Google Scholar
• ZhangMZhangZGarmestaniKActivating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemiaCancer Res2004645825582915313926
   PubMed Web of Science ®Google Scholar
• BachaPForteSKassamNPharmacokinetics of the recombinant fusion protein DAB486IL-2 in animal modelsCancer Chemother Pharmacol1990264094142225311
   PubMed Web of Science ®Google Scholar
• WilliamsDPParkerKBachaPDiphtheria toxin receptor binding domain substitution with interleukin-2: genetic construction and properties of a diphtheria toxin-related interleukin-2 fusion proteinProtein Eng198714934983334101
   PubMedGoogle Scholar
• LeMaistreCFMeneghettiCRosenblumMPhase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptorBlood199279254725541586707
   PubMed Web of Science ®Google Scholar
• LeMaistreCFSalehMNKuzelTMPhase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2Blood1998913994059427692
   PubMed Web of Science ®Google Scholar
• WilliamsDPSniderCEStromTBMurphyJRStructure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of targeT-cellsJ Biol Chem199026511885118892195027
   PubMed Web of Science ®Google Scholar
• AttiaPMakerAVHaworthLRRogers-FreezerLRosenbergSAInability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T-lymphocytes in patients with melanomaJ Immunother20052858259216224276
   PubMed Web of Science ®Google Scholar
• TalpurRJonesDMAlencarAJCD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphomaJ Invest Dermatol200612657558316410787
   PubMed Web of Science ®Google Scholar
• SalehMNLeMaistreCFKuzelTMAntitumor activity of DAB389IL-2 fusion toxin in mycosis fungoidesJ Am Acad Dermatol19983963739674399
   PubMed Web of Science ®Google Scholar
• DuvicMCatherJMaizeJFrankelAEDAB389IL2 diphtheria fusion toxin produces clinical responses in tumor stage cutaneous T-cell lymphomaAm J Hematol19985887909590158
   PubMed Web of Science ®Google Scholar
• OlsenEDuvicMFrankelAPivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphomaJ Clin Oncol20011937638811208829
   PubMed Web of Science ®Google Scholar
• Negro-VilarADziewanowskaZGrovesESEfficacy and safety of denileukin diftitox (Dd) in a phase III, double-blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL)J Clin Oncol (Meeting Abstracts)2007258026
   Web of Science ®Google Scholar
• Negro-VilarAPrinceHMDuvicMRichardsonSSunYAcostaMEfficacy and safety of denileukin diftitox (Dd) in cutaneous T-cell lymphoma (CTCL) patients: Integrated analysis of three large phase III trialsJ Clin Oncol262008520suppl abstr 8551
   Google Scholar
• MahrleGThieleBRetinoids in cutaneous T-cell lymphomasDermatologica1987175Suppl 11451503500880
   PubMedGoogle Scholar
• GorgunGFossFImmunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitoxBlood20021001399140312149223
   PubMed Web of Science ®Google Scholar
• FossFDemierreMFDiVenutiGA phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphomaBlood200510645445715811959
   PubMed Web of Science ®Google Scholar
• ShaoRHTianXGorgunGUrbanoAGFossFMArginine butyrate increases the cytotoxicity of DAB(389)IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rbeta geneLeuk Res2002261077108312443879
   PubMed Web of Science ®Google Scholar
• DuvicMKuzelTMOlsenEAQuality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)Clin Lymphoma2002222222811970761
   PubMedGoogle Scholar
• CellaDFTulskyDSGrayGThe Functional Assessment of Cancer Therapy scale: development and validation of the general measureJ Clin Oncol1993115705798445433
   PubMed Web of Science ®Google Scholar
• DangNHFayadLMcLaughlinPPhase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaBr J Haematol200713850250517608763
   PubMed Web of Science ®Google Scholar
• GhoriFPolderKDPinter-BrownLCThyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoidesJ Clin Endocrinol Metab2006912205220816595600
   PubMed Web of Science ®Google Scholar
• RuddleJBHarperCAHonemannDSeymourJFPrinceHMA denileukin diftitox (Ontak) associated retinopathy?Br J Ophthalmol2006901070107116854841
   PubMed Web of Science ®Google Scholar
• AvarbockABLorenAWParkJYLethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T-cell lymphoma and occult cirrhosisAm J Hematol20088359359518335564
   PubMed Web of Science ®Google Scholar